• Top 10 Patient Safety Concerns of 2025: A Pharmacy-Focused Review

    Every clinician enters practice with a commitment to “do no harm,” yet preventable harm occurs daily in healthcare settings. While unintentional, these safety challenges persist because interventions often remain fragmented and reactive, not from lack of effort.Each year, ECRI and the Institute for Safe Medication Practices (ISMP) develop the Top 10 Patient Safety Concerns by analyzing scientific literature, patient safety events, adverse event reports, and conversations with healthc
  • Endocrinology PharmDs Show Value at Nebraska Medicine

    By Karen BlumAs the focus of type 2 diabetes management has shifted from lowering hemoglobin A1c (HbA1c) to reducing overall comorbidity risk, pharmacists at Nebraska Medicine are demonstrating their clinical value through the development of an ambulatory care pharmacist service line.“The first thing that we did when I took over in this position [in January 2023] is revamp what it is that the pharmacist did,” said Caressa Trueman, PharmD, BCACP, BC-ADM, an ambulatory care pharmacist
  • Debating the Merits of Ceftriaxone Versus Cefazolin for MSSA Therapy

    By Karen BlumHunter Rondeau, PharmDWhether ceftriaxone or cefazolin is preferred in the management of methicillin-susceptible Staphylococcus aureus (MSSA) was the subject of a good-natured, lively debate at the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.MSSA is more common than its more resistant counterpart, methicillin-resistant S. aureus (MRSA), said Hunter Rondeau, PharmD, BCIDP, AAHIVP, an antimicrobial stewardship coordinator at SSM Health in St. Louis. Risk factors
  • Genetics and Drugs: A Tricky Interplay

    By Karen BlumPharmacogenomic testing to determine how a patient’s genetic variations influence their response to medications can be helpful in some cases in selecting medications, but it’s still an evolving science, speakers noted during the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.“We think about pharmacogenomics as being something that is a black-and-white report, and it very much is not,” said Jordan Baye, PharmD, BCPS, a clinical pharmacist at
  • Advertisement

  • U.S. Drug Spending a 2-Sided Coin

    By Susan Kreimer and Gina ShawTwo new reports on healthcare spending appear to point in opposite directions: One shows U.S. prescription drug outlays surging toward $1 trillion per year, while the other finds that pharmacy price increases are no longer the primary driver of hospital cost inflation. But site-of-care trends actually link both findings.Pharmacy price growth is projected at 2.84%, a decline from 3.35% six months ago, according to the inflation report, by Vizient. The moderation refl
  • How Do You Treat HIV?

    By Meaghan Lee CallaghanWith more treatment options than ever, how do you navigate managing patients living with HIV in the clinic or in the hospital?Amanda Binkley, PharmD, BCIDP, AAHIVP; David Cluck, PharmD, FIDSA, BCPS, BCIDP, AAHIVP; and Andrea Pallotta, PharmD, BCIDP, AAHIVP, sat down with Infectious Disease Special Edition right after their session during a workshop at the newly combined Making a Difference in Infectious Diseases (MAD-ID) and Society of Infectious Disease Pharmacists (SIDP
  • IV Workflow Management Systems Keep Pace With Expanding Ambulatory Infusion Market

    By Gina ShawIV workflow management systems (IVWMS) have long been a fixture of inpatient sterile compounding, and their footprint is expanding rapidly. Health systems are now pushing these platforms into ambulatory infusion centers, 503B outsourcing facilities, and home infusion pharmacies, each of which carries its own safety demands, regulatory requirements, and operational constraints.“This is encouraging,” said Mark Neuenschwander, the founding director of the THRIV Coalition for
  • Pharmacists Power VA’s Rapid Scale-up Of Precision Medicine

    By Karen BlumWhen the Veterans Health Administration sought to expand its infrastructure to implement pharmacogenomic (PGx) testing across its medical centers, it turned to a valuable resource: pharmacists.In one recent two-month sampling, the PGx program the VA built in response identified 193 high-priority drug–gene interactions, 95% of which were addressed in less than two weeks, reported Bonnie Balderose, PharmD, who described the program’s evolution in an ASHP Best Practices Awa
  • Advertisement

  • Rebuilding the Hazardous Drug List:

    Charlotte A. Smith, RPh, MSSenior Regulatory AdvisorRanee Runnebaum, PharmDManager, Regulatory and ComplianceKathleen Skibinski, RPh, MSRegulatory ConsultantWMHS PharmEcology ServicesThe National Institute for Occupational Safety and Health (NIOSH) Hazardous Drug List 20241 is the most recent official publication to delineate hazardous drugs in the United States. Although it provides a solid framework for moving drug evaluations forward, it has not been updated to include drugs approved in the l
  • Quality by Design in Home Infusion Cleanrooms

    By Gina Shaw Kevin Hansen, PharmDWhen a hospital pharmacy’s cleanroom goes down, an adjacent cleanroom on campus can usually cover. When a home infusion pharmacy’s cleanroom goes down, the challenge is far greater, experts noted during a session at NHIA26, in Denver.“Health-system pharmacies may have a multitude of cleanrooms,” said Kevin Hansen, PharmD, MS, BCSCP, the senior director of pharmacy compounding services at Premier Inc., in a presentation at NHIA. “For
  • Filling the IV Daptomycin Dosing Knowledge Gap

    By Marcus A. BanksIntravenous daptomycin is a valuable alternative to vancomycin when treating methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections and endocarditis, given its reduced risk for nephrotoxicity and infusion reactions.The Clinical and Laboratory Standards Institute recommends indication-specific dosing for daptomycin that includes 8 to 10 mg/kg for MRSA infections and 10 to 12 mg/kg for endocarditis or vancomycin-resistant enterococci (VRE) bacteremia (Clin Infe
  • Smart Speakers Boost NICU Medication Access

    By Marcus A. BanksSmart speaker announcements of STAT medication orders have sped medication delivery in the neonatal ICU (NICU) at Houston Methodist The Woodlands Hospital (The Woodlands), according to a study (poster 4-059) presented at the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.The speaker enables pharmacists and technicians to learn about STAT orders without being tethered to their computers. “Having that audible alert lets everyone know that there’s a
  • MAD-ID/SIDP Meeting Showcases the Rigor Of ID Pharm Research

    The research acumen of infectious diseases pharmacists was on display at the newly combined Making a Difference in Infectious Diseases and Society of Infectious Diseases Pharmacists 2026 meeting, in Orlando, Florida.Two cases in point are a pharmacist-led IV-to-oral conversion protocol that reduced hospital length of stay (LOS) and yielded year-to-date savings of nearly $500,000, plus efficacy data suggesting that pritelivir (AiCuris), an investigational helicase-primase inhibitor, deserves to b
  • The Wounded Healer: Confronting Compassion Fatigue and Moral Injury

    Originally published by our sister publication Anesthesiology NewsD. John Doyle, MD, PhD, DPhilEmeritus Professor of AnesthesiologyCase Western Reserve UniversityClevelandConsultant AnesthesiologistDepartment of General AnesthesiologyCleveland ClinicEven the most committed caregivers, those who lead with empathy, skill, and purpose, are not invulnerable. In fact, it is often the most devoted who find themselves most deeply affected by the emotional weight of their work. Repeated exposure to suff
  • FDA Approves Bizengri for NRG1 Fusion–Positive Cholangiocarcinoma

    Originally published by our sister publication Gastroenterology & Endoscopy NewsBy GEN StaffThe FDA has approved zenocutuzumab (Bizengri, Partner Therapeutics) for adults with NRG1 fusion–positive cholangiocarcinoma and disease progression on or after prior systemic therapy, making it the first drug approved for people with the NRG1 gene fusion and this aggressive cancer that forms in the bile ducts.“Patients with this ultra-rare type of cancer desperately need new treatment opti
  • EHR “Nudge” Helps Withhold CDI Therapy Safely in Colonized Patients

    Originally published by our sister publication Infectious Disease Special EditionBy Gina ShawWithholding therapy for Clostridioides difficile in patients meeting criteria for C. difficile colonization was not associated with worse clinical outcomes, with no patients experiencing a 90-day C. difficile-related readmission, according to a retrospective cohort study presented by investigators from Henry Ford Hospital in Detroit at the newly combined Making a Difference in Infectious Diseases (MAD-ID

Follow @newsl_pharmacy on Twitter!